Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
LBT Innovations Ltd. engages in the business of researching, developing, and commercializing innovative technologies for healthcare and laboratory supply markets. It operates through the following geographical regions: Australia, Switzerland, the United States, Sweden, the United Kingdom, and Germany. The company was founded by Lusia Halina Guthrie, Douglas Peter LeMessurier, and Paul Andrew Mariani in 2004 and is headquartered in Adelaide, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.04
Trade Value (12mth)
AU$11,346.00
1 week
0%
1 month
14.29%
YTD
60%
1 year
166.67%
All time high
0.76
EPS 3 yr Growth
-77.40%
EBITDA Margin
-358.40%
Operating Cashflow
-$4m
Free Cash Flow Return
-98.00%
ROIC
-99.80%
Interest Coverage
-11.60
Quick Ratio
2.60
Shares on Issue (Fully Dilluted)
1554m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
14 October 24 |
Notification of cessation of securities - LBT
×
Notification of cessation of securities - LBT |
11 October 24 |
Proposed issue of securities - LBT
×
Proposed issue of securities - LBT |
10 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
09 October 24 |
APAS Showcased at High Profile US Pharmaceutical Conference
×
APAS Showcased at High Profile US Pharmaceutical Conference |
08 October 24 |
Notification of cessation of securities - LBT
×
Notification of cessation of securities - LBT |
01 October 24 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
18 September 24 |
Director Appointment/Resignation
×
Director Appointment/Resignation |
16 September 24 |
Change in substantial holding
×
Change in substantial holding |
16 September 24 |
Application for quotation of securities - LBT
×
Application for quotation of securities - LBT |
16 September 24 |
Application for quotation of securities - LBT
×
Application for quotation of securities - LBT |
13 September 24 |
Change in substantial holding
×
Change in substantial holding |
13 September 24 |
Change in substantial holding - corrected
×
Change in substantial holding - corrected |
12 September 24 |
Application for quotation of securities - LBT
×
Application for quotation of securities - LBT |
12 September 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
12 September 24 |
Change in substantial holding
×
Change in substantial holding |
09 September 24 |
Application for quotation of securities - LBT
×
Application for quotation of securities - LBT |
30 August 24 |
Application for quotation of securities - LBT
×
Application for quotation of securities - LBT |
30 August 24 |
Notification regarding unquoted securities - LBT
×
Notification regarding unquoted securities - LBT |
29 August 24 |
Appendix 4E
×
Appendix 4E |
29 August 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 August 24 |
Corporate Governance Statement
×
Corporate Governance Statement |
29 August 24 |
Appendix 4G
×
Appendix 4G |
27 August 24 |
Application for quotation of securities - LBT
×
Application for quotation of securities - LBT |
26 August 24 |
Development to Expand Pharma Market Opportunity
×
Development to Expand Pharma Market Opportunity |
26 August 24 |
Proposed issue of securities - LBT
×
Proposed issue of securities - LBT |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.